

# Dafna D Gladman

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6737587/dafna-d-gladman-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

547  
papers

43,454  
citations

92  
h-index

196  
g-index

702  
ext. papers

51,060  
ext. citations

5.5  
avg, IF

7.38  
L-index

#	Paper	IF	Citations
547	Exploring cannabis use and perspectives among psoriatic disease patients.. <i>Clinical Rheumatology</i> , <b>2022</b> , 1	3.9	0
546	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis.. <i>Seminars in Arthritis and Rheumatism</i> , <b>2022</b> , 53, 151950	5.3	
545	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.. <i>Arthritis Research and Therapy</i> , <b>2022</b> , 24, 40	5.7	1
544	Correspondence on No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related physician-reported spondylitis by Braun and Landewijde <i>Annals of the Rheumatic Diseases</i> , <b>2022</b> ,	2.4	1
543	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1231-1235	4.7	10
542	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	4
541	Assessment of the Toronto Psoriatic Arthritis Screen 2 as a Screening Tool for Psoriasis. <i>Journal of Cutaneous Medicine and Surgery</i> , <b>2021</b> , 12034754211061085	1.6	
540	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2021</b> , 13, 1759720X211057975	3.8	1
539	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1789-1808	4.4	4
538	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1789-1795	4.7	2
537	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , <b>2021</b> ,	4.1	4
536	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 94	5.7	2
535	Medium versus high initial prednisone dose for remission induction in lupus nephritis: A propensity score matched analysis. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	3
534	Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients with Psoriatic Arthritis. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	3
533	Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 464-468	5.3	6
532	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e270-e283	14.2	7
531	Evolving concepts in systemic lupus erythematosus damage assessment. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 307-308	8.1	3

530	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 367-386	5.3	
529	Axial Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , <b>2021</b> , 23, 35	4.9	2
528	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1547-1551	4.1	1
527	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , <b>2021</b> , 30, 1283-1288	2.6	2
526	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 2293-2302	9.5	2
525	Canadian Rheumatologists' Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1692-1697	4.1	1
524	Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1429-1435	2.4	3
523	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 547-552	5.3	3
522	Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. <i>Rheumatology International</i> , <b>2021</b> , 41, 1457-1464	3.6	2
521	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , <b>2021</b> , 3, 550-557	3.5	2
520	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 67-73	4.1	8
519	Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 680-686	4.7	2
518	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 321-325	4.1	4
517	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 1-2	2.4	21
516	Disease development and outcome <b>2021</b> , 37-45		
515	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B27 Status?. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 856-860	4.7	17
514	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 58-66	4.1	3
513	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , <b>2021</b> , 60, 73-80	3.9	1

512	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 852-858	4.1	4
511	Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1302-1309	4.5	4
510	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 228-231	4.1	1
509	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , <b>2021</b> , 60, 1137-1147	3.9	7
508	New EULAR/ACR 2019 SLE Classification Criteria: defining ominosity in SLE. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	6
507	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 29	5.7	9
506	Metrics in Disease Activity Measures in Systemic Lupus Erythematosus <b>2021</b> , 111-146		
505	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	10
504	Incidence of and Risk Factors for Heart Failure in Patients with Psoriatic Disease - A Cohort Study. <i>Arthritis Care and Research</i> , <b>2021</b> ,	4.7	4
503	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 144-149	5.3	4
502	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , <b>2021</b> , 60, 4737-4747	3.9	5
501	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , <b>2021</b> , 30, 867-875	2.6	3
500	Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1223-1240	4.4	2
499	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , <b>2021</b> , 73, 1243-1249	4.7	5
498	Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. <i>Journal of Rheumatology</i> , <b>2021</b> , 48, 1824-1829	4.1	0
497	Axial involvement in psoriatic arthritis: An update for rheumatologists. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 880-887	5.3	8
496	Response to: Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE" by Whittall Garcia. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> ,	2.4	
495	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology, The</i> , <b>2021</b> , 3, e715-e723	14.2	14

494	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , <b>2021</b> , 51, 1117-1124	5.3	1
493	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies.. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.6	5
492	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. <i>Rheumatology and Therapy</i> , <b>2021</b> , 8, 1677-1691	4.4	
491	Prevalence and factors associated with osteoporosis and bone mineral density testing in psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	1
490	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI). <i>Arthritis Care and Research</i> , <b>2020</b> ,	4.7	2
489	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , <b>2020</b> , 93, 100601	2.4	3
488	The Relationship Between Physical Examination and Ultrasonography of Large Enteses of the Achilles Tendon and Patellar Tendon Origin. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1026-1030	4.1	8
487	Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1644-1651	4.1	8
486	Case Report of Refractory Psoriatic Arthritis Achieving Remission Using (Black Seed Oil) Extract. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1297	4.1	1
485	Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 571-575	5.3	12
484	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , <b>2020</b> , 7, 553-580	4.4	29
483	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1734-1740	9.5	7
482	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 612-617	2.4	17
481	Treatment guidelines in psoriatic arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, i37-i46	3.9	44
480	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 18	5.7	13
479	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	17
478	Remission in psoriatic arthritis: Definition and predictors. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1494-1499	5.3	1
477	Declining levels of serum chemokine (C-X-C motif) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?. <i>British Journal of Dermatology</i> , <b>2020</b> , 183, 920-927	4	6

476	Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 294-299	3.5	16
475	Liver Abnormalities in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 847-853	4.1	5
474	Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 66-71	4.1	11
473	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , <b>2020</b> , 96, 53-57	4.1	6
472	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1800-1808	4.7	7
471	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 658-666	9.5	11
470	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , <b>2020</b> , 106, 102340	15.5	15
469	Treatment-to-Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 814-821	4.7	1
468	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 356-362	2.4	18
467	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2020</b> , 5, 12-22	1.1	3
466	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , <b>2020</b> , 4, rkaa032	1.1	1
465	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	12
464	Long-Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 459-470	3.5	3
463	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1333-1339	2.4	16
462	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2020</b> , 50, 1158-1181	5.3	4
461	The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 69-76	3.9	8
460	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , <b>2020</b> , 59, 90-98	3.9	21
459	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 539-547	4.1	12



458	Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 362-368	4.1	10
457	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 72-81	4.1	21
456	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 854-864	4.1	7
455	Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. <i>Rheumatology</i> , <b>2020</b> , 59, 1340-1346	3.9	42
454	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , <b>2020</b> , 72, 1579-1588	4.7	4
453	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 67-77	9.5	18
452	Predictive Utility of Cardiovascular Risk Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 928-938	4.1	15
451	Response to: Can biomarkers differentiate psoriatic arthritis from osteoarthritis? by Tian. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, e113	2.4	1
450	Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	13
449	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. <i>Journal of Rheumatology</i> , <b>2020</b> , 47, 1366-1373	4.1	3
448	Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 38	5.7	23
447	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1651-1659	9.5	15
446	Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase III and Long-Term Extension Studies. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1387-1395	4.7	21
445	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis. <i>Arthritis Research and Therapy</i> , <b>2019</b> , 21, 118	5.7	28
444	A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 49, 241-245	5.3	2
443	All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 802-806	2.4	52
442	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1089-1096	4.1	21
441	Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 796-801	2.4	18

440	Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC. <i>Frontiers in Genetics</i> , <b>2019</b> , 10, 304	4.5	5
439	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1297-1307	9.5	15
438	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 996-1005	4.1	21
437	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , <b>2019</b> , 58, 1259-1267	3.9	5
436	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 64-69	4.1	10
435	Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 893-902	4.7	46
434	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 822-828	4.7	25
433	The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 638-643	5.3	13
432	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1151-1159	2.4	344
431	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1400-1412	9.5	488
430	Dr. Tselios, reply. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 1422	4.1	
429	Psoriatic arthritis. <i>F1000Research</i> , <b>2019</b> , 8,	3.6	45
428	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , <b>2019</b> , 95, 33-37	4.1	9
427	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , <b>2019</b> , 95, 54-57	4.1	6
426	Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. <i>PLoS ONE</i> , <b>2019</b> , 14, e0212043	3.7	14
425	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1112-1124	9.5	94
424	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , <b>2019</b> , 5, e000806	5.9	24
423	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. <i>RMD Open</i> , <b>2019</b> , 5, e000808	5.9	26



422	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. <i>RMD Open</i> , <b>2019</b> , 5, e001002	5.9	7
421	Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Population-Based Study. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 1084-1091	4.7	33
420	Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 834-839	5.3	6
419	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1010-1012	2.4	4
418	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 721-726	4.1	29
417	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 990-995	4.1	26
416	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , <b>2019</b> , 4, 31-58	1.1	6
415	Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 266-273	4.1	7
414	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 281-289	9.5	31
413	Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. <i>Journal of Rheumatology</i> , <b>2019</b> , 46, 391-396	4.1	20
412	How can we define low disease activity in systemic lupus erythematosus?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2019</b> , 48, 1035-1040	5.3	15
411	Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 895-902	3.9	13
410	Disease course patterns in systemic lupus erythematosus. <i>Lupus</i> , <b>2019</b> , 28, 114-122	2.6	23
409	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 5-32	9.5	178
408	Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , <b>2019</b> , 71, 2-29	4.7	137
407	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. <i>Clinical Rheumatology</i> , <b>2019</b> , 38, 1063-1066	3.9	2
406	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , <b>2019</b> , 80, 251-265.e19	4.5	186
405	Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). <i>RMD Open</i> , <b>2018</b> , 4, e000606	5.9	13

404	A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. <i>Rheumatology</i> , <b>2018</b> , 57, 1370-1376	3.9	16
403	The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 756-762	9.5	12
402	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 378-384	4.1	27
401	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 393-396	4.1	23
400	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , <b>2018</b> , 57, 677-687	3.9	20
399	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 367-377	4.1	74
398	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1478-1487	4.7	36
397	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 3-17	2.4	320
396	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, e23	2.4	10
395	From Childhood to Adulthood: Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 750-757	4.7	11
394	Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 408-416	9.5	33
393	Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. <i>Journal of Medical Economics</i> , <b>2018</b> , 21, 163-173	2.4	12
392	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 47, 654-665	5.3	32
391	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , <b>2018</b> , 57, 1777-1788	3.9	15
390	Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 1573-1577	2.4	22
389	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1440-1447	4.1	10
388	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies. <i>RMD Open</i> , <b>2018</b> , 4, e000669	5.9	19
387	Patterns of peripheral joint involvement in psoriatic arthritis-Symmetric, ray and/or row?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 430-435	5.3	6

386	Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. <i>Nature Reviews Rheumatology</i> , <b>2018</b> , 14, 363-371	8.1	83
385	Functional impairment measurement in psoriatic arthritis: Importance and challenges. <i>Seminars in Arthritis and Rheumatism</i> , <b>2018</b> , 48, 436-448	5.3	16
384	Physician® Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1256-1262	4.1	6
383	SAT0270 Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis <b>2018</b> ,		2
382	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2018</b> , 94, 17-25	4.1	8
381	The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. <i>Journal of Rheumatology</i> , <b>2018</b> , 94, 26-29	4.1	3
380	Addressing comorbidities in psoriatic disease. <i>Rheumatology International</i> , <b>2018</b> , 38, 219-227	3.6	8
379	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2018</b> , 70, 345-355	9.5	51
378	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 1294-1302	4.7	13
377	Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 213-217	4.1	15
376	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 90-94	4.1	12
375	SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study <b>2018</b> ,		3
374	Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. <i>Nature Communications</i> , <b>2018</b> , 9, 4178	17.4	61
373	Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2018</b> , 32, 415-426	5.3	1
372	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , <b>2018</b> , 392, 2367-2377	4.0	107
371	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , <b>2018</b> , 5, 246	4.9	15
370	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2018</b> , 45, 1426-1439	4.1	33
369	Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 486-489	2.2	8

368	Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 252-256	4.7	7
367	The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 286-291	4.1	26
366	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1522-1528	4.1	66
365	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1700-1705	4.7	10
364	From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1627-1635	4.7	26
363	Psoriasis in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 879-884	3.9	16
362	The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 437-443	4.1	29
361	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 957-970	59.2	586
360	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 79-87	2.4	341
359	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 673-680	2.4	138
358	Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 740-745	5.3	32
357	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 31	5.7	9
356	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1550-1558	2.4	129
355	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1591-1597	2.4	33
354	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 697-700	4.1	29
353	Benchmarking Care in Psoriatic Arthritis - The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 674-678	4.1	15
352	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1173-1178	4.1	21
351	Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1369-1374	4.1	24

350	Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 1773-1778	3.9	5
349	Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. <i>Pediatric Rheumatology</i> , <b>2017</b> , 15, 18	3.5	8
348	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 2095-6	59.2	60
347	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. <i>Nature Communications</i> , <b>2017</b> , 8, 15382	17.4	136
346	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 519-534	4.1	14
345	Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1685-1691	4.7	80
344	Should methotrexate remain the first-line drug for psoriasis?. <i>Lancet, The</i> , <b>2017</b> , 389, 482-483	4.0	6
343	Epigenetics of psoriatic disease: A systematic review and critical appraisal. <i>Journal of Autoimmunity</i> , <b>2017</b> , 78, 29-38	15.5	46
342	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1841-1849	4.1	32
341	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1525-1536	59.2	276
340	The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , <b>2017</b> , 19, 189	5.7	38
339	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , <b>2017</b> , 8, 16021	17.4	171
338	Magnetic Resonance Imaging in Psoriatic Arthritis: A Descriptive Study of Indications, Features and Effect on Treatment Change. <i>Journal of Clinical Rheumatology</i> , <b>2017</b> , 23, 243-245	1.1	10
337	Reply. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 1934	4.7	
336	Association of variably expressed KIR3dl1 alleles with psoriatic disease. <i>Clinical Rheumatology</i> , <b>2017</b> , 36, 2261-2266	3.9	14
335	The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2017</b> , 69, 622-629	9.5	63
334	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , <b>2017</b> , 46, 791-797	5.3	3
333	Defining Low Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , <b>2017</b> , 69, 997-1003	4.7	45

332	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. <i>RMD Open</i> , <b>2017</b> , 3, e000415	5.9	19
331	Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. <i>Lupus Science and Medicine</i> , <b>2017</b> , 4, e000239	4.6	60
330	OP0202 Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial <b>2017</b> ,		2
329	FRI0509 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study <b>2017</b> ,		6
328	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 1680-6	2.4	62
327	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , <b>2016</b> , 55, 252-62	3.9	210
326	Psoriasis. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16082	51.1	327
325	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 965-9	4.1	22
324	Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 970-3	4.1	3
323	Presidential Round Table: A Report from the GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 986-9	4.1	0
322	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1057-62	4.1	4
321	Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 46, 174-182	5.3	26
320	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 979-85	4.1	2
319	The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 915-23	9.5	119
318	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1060-71	9.5	485
317	The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 362-6	4.1	21
316	Historical Perspectives on Psoriatic Arthritis <b>2016</b> , 3-6		1
315	GRAPPA Historical Perspective <b>2016</b> , 7-14		



314	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 54-65	4.1	47
313	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo-Controlled Study. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 267-74	4.7	57
312	Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 875-9	4.1	46
311	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 604-10	5.3	56
310	Recent advances in understanding and managing psoriatic arthritis. <i>F1000Research</i> , <b>2016</b> , 5, 2670	3.6	20
309	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1932-44	9.5	27
308	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , <b>2016</b> , 2, e000217	5.9	31
307	Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. <i>Arthritis Research and Therapy</i> , <b>2016</b> , 18, 296	5.7	23
306	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1844-1851	4.1	8
305	Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 2911-2916	9.5	49
304	Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2016</b> , 43, 1718-23	4.1	13
303	On Modelling Minimal Disease Activity. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 388-93	4.7	4
302	Interferon- $\gamma$ Induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , <b>2015</b> , 58, 100-10	15.5	29
301	Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2198-203	4.1	29
300	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1048-1051	4.1	6
299	ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patients. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1627-9	2.4	63
298	Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 813-7	2.4	108
297	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 1837-47	9.5	77

296	What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. <i>Current Opinion in Rheumatology</i> , <b>2015</b> , 27, 91-8	5.3	26
295	Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 810-6	4.1	21
294	Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 841-6	4.1	37
293	Atherosclerosis in psoriatic disease: latest evidence and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , <b>2015</b> , 7, 187-95	3.8	37
292	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. <i>Nature Genetics</i> , <b>2015</b> , 47, 1085-90	36.3	112
291	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1401-5	4.1	5
290	Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2015</b> , 41, 569-79	2.4	80
289	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>American Journal of Human Genetics</i> , <b>2015</b> , 97, 816-36	11	185
288	Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 2318-26	4.1	14
287	Toward Treating to Target in Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2015</b> , 93, 14-6		2
286	Minimal disease activity and anti-tumor necrosis factor therapy in psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 842-7	4.7	35
285	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1530-6	2.4	51
284	Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1830-5	2.4	50
283	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1706-13	2.4	250
282	Gene expression differences between psoriasis patients with and without inflammatory arthritis. <i>Journal of Investigative Dermatology</i> , <b>2015</b> , 135, 620-623	4.3	26
281	DEVELOPING AN IPAD™ APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC. <i>International Journal of Technology Assessment in Health Care</i> , <b>2015</b> , 31, 99-102	1.8	3
280	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Entesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 1041-1043	4.1	2
279	SAT0404 Spot Urine Protein/Creatinine Ratio is Useful in Screening for Proteinuria but Should Not Substitute 24 hours Urine Collection Sample to Quantify Proteinuria in Lupus. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 805.2-806	2.4	

278	Further Evidence Supporting a Parent-of-Origin Effect in Psoriatic Disease. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 1586-90	4.7	11
277	AB0822 Therapeutic Response in Adalimumab-Treated Patients with Psoriatic Arthritis in Relation to Weight. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1175.1-1175	2.4	2
276	Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 479-88	4.1	101
275	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , <b>2015</b> , 6, 7146	17.4	164
274	Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. <i>Arthritis Care and Research</i> , <b>2015</b> , 67, 264-72	4.7	54
273	Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. <i>Nature Communications</i> , <b>2015</b> , 6, 7001	17.4	122
272	Is it time for treat to target in psoriatic arthritis?. <i>Lancet, The</i> , <b>2015</b> , 386, 2450-2	4.0	2
271	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 296	5.7	13
270	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 665-81	4.1	27
269	2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 654-64	4.1	23
268	Isolated hematuria and sterile pyuria may indicate systemic lupus erythematosus activity. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 437-40	4.1	11
267	Management of psoriatic arthritis <b>2015</b> , 1008-1013		
266	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 138-42	2.4	83
265	Tumour necrosis factor $\beta$ blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1007-11	2.4	42
264	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? a critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , <b>2014</b> , 43, 521-5	5.3	28
263	Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. <i>Rheumatology</i> , <b>2014</b> , 53, 233-9	3.9	38
262	Immunoglobulin G subclass analysis in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2421-4	4.1	2
261	Updated guidelines for the management of axial disease in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 2286-9	4.1	27

260	Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1194-6	4.1	2
259	Is the MADrid Sonographic Enthesitis Index useful for differentiating psoriatic arthritis from psoriasis alone and healthy controls?. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 466-72	4.1	59
258	Depression and anxiety in psoriatic disease: prevalence and associated factors. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 887-96	4.1	138
257	Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , <b>2014</b> , 71, 649-55	4.5	42
256	The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients. <i>Lupus</i> , <b>2014</b> , 23, 1142-8	2.6	20
255	Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. <i>American Journal of Human Genetics</i> , <b>2014</b> , 95, 162-72	11	151
254	Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 688-97	4.1	57
253	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1020-6	2.4	305
252	The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1990-6	2.4	67
251	AB0160 Epigenetic Studies in Maternally versus Paternally Transmitted Psoriatic Disease. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 856.1-856	2.4	6
250	FRI0165 The Molecular Convergence of Non-Hla Ankylosing Spondylitis Risk Genes with Autoimmune Diseases. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 441.3-442	2.4	
249	OP0042 Do We Know How and When to Stop Immunosuppressants in Lupus Patients?. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 76-76	2.4	2
248	Qualifying unmet needs and improving standards of care in psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1759-66	4.7	57
247	Development of criteria to distinguish inflammatory from noninflammatory arthritis, enthesitis, dactylitis, and spondylitis: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1249-51	4.1	23
246	Prolonged clinical remission in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1808-16	4.1	68
245	Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1206-11	4.1	12
244	Predictors for clinical outcome in psoriatic arthritis - what have we learned from cohort studies?. <i>Expert Review of Clinical Immunology</i> , <b>2014</b> , 10, 763-70	5.1	13
243	The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meeting. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 1227-9	4.1	16

242	Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , <b>2014</b> , 41, 782-91	4.1	30
241	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. <i>Lupus Science and Medicine</i> , <b>2014</b> , 1, e000031	4.6	53
240	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1689-94	2.4	100
239	Reliability of radiographic scoring methods in axial psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 1417-22	4.7	19
238	Outcome Measures in Psoriatic Disease. <i>Current Dermatology Reports</i> , <b>2013</b> , 2, 164-171	1.5	
237	Psoriatic arthritis: phenotypic variance and nosology. <i>Current Rheumatology Reports</i> , <b>2013</b> , 15, 316	4.9	26
236	Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2013</b> , 51, 317-25	5.9	25
235	Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?. <i>Lupus</i> , <b>2013</b> , 22, 1243-50	2.6	36
234	Cancer risk in systemic lupus: an updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , <b>2013</b> , 42, 130-5	15.5	194
233	Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2887-97		65
232	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , <b>2013</b> , 13, 723-37	5.4	19
231	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , <b>2013</b> , 8, S46-S53	0.5	7
230	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , <b>2013</b> , 69, 729-735	4.5	287
229	Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 578-82	2.4	56
228	Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. <i>Human Immunology</i> , <b>2013</b> , 74, 1333-8	2.3	38
227	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , <b>2013</b> , 45, 730-8	36.3	551
226	Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 866-71	4.1	41
225	Incremental effects of comorbidity on quality of life in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1349-56	4.1	62

224	Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1956-61	2.4	75
223	The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 831-41	4.1	79
222	Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1777-85	2.4	70
221	Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis. <i>Rheumatology</i> , <b>2013</b> , 52, 705-11	3.9	14
220	Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 1504-9		52
219	Diffuse idiopathic skeletal hyperostosis in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1367-73	4.1	25
218	A hot spot for systemic lupus erythematosus, but not for psoriatic arthritis, identified by spatial analysis suggests an interaction between ethnicity and place of residence. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 1579-85		7
217	Vaccination and auto-immune rheumatic diseases: lessons learnt from the 2009 H1N1 influenza virus vaccination campaign. <i>Current Opinion in Rheumatology</i> , <b>2013</b> , 25, 164-70	5.3	7
216	Damage in lupus patients--what have we learned so far?. <i>Lupus</i> , <b>2013</b> , 22, 1225-31	2.6	12
215	Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1407-9	4.1	4
214	The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 715-20	2.4	57
213	Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1357-9	4.1	57
212	Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational cohort study. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 630-3	4.1	14
211	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 986-91	2.4	192
210	OP0095 Customized CNV microarray identified UGT2B17 as a novel susceptibility gene associated with familial ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 71, 85.1-85	2.4	
209	Clinical Measures, Metrics, and Indices <b>2013</b> , 563-581		3
208	Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. <i>Rheumatology</i> , <b>2012</b> , 51, 571-6	3.9	143
207	Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 50-5	2.4	104



206	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 3052-3		13
205	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , <b>2012</b> , 44, 1341-8	36.3	681
204	Early psoriatic arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>2012</b> , 38, 373-86	2.4	45
203	Spondyloarthritis <b>2012</b> , 367-379		
202	Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 511-8	4.7	60
201	Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. <i>Arthritis Care and Research</i> , <b>2012</b> , 64, 758-65	4.7	42
200	Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2504-17		151
199	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 2677-86		2688
198	Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL. <i>Journal of Investigative Dermatology</i> , <b>2012</b> , 132, 1133-40	4.3	89
197	On defining musculoskeletal inflammation: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2214-5	4.1	3
196	Does the change in season affect disease activity in patients with psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1370-3	2.4	5
195	Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. <i>Rheumatology</i> , <b>2012</b> , 51, 552-6	3.9	100
194	Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2181-3	4.1	5
193	Biomarkers for comorbidities in psoriasis: a report from the GRAPPA 2011 annual meeting. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 2193-5	4.1	2
192	Dr. Cauli, et al reply: Table 1.. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 654-654	4.1	
191	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1502-9	2.4	115
190	Future trends in research in psoriatic arthritis. <i>Journal of rheumatology Supplement, The</i> , <b>2012</b> , 89, 106-10		4
189	Psoriatic arthritis in Canadian clinical practice: the PsA assessment in rheumatology. <i>Journal of Rheumatology</i> , <b>2012</b> , 39, 1850-3	4.1	10

188	Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1361-5	2.4	26
187	Gender-related differences in patients with psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , <b>2012</b> , 7, 641-649	1.5	9
186	Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. <i>Rheumatology</i> , <b>2011</b> , 50, 25-31	3.9	93
185	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , <b>2011</b> , 13, R156	5.7	61
184	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , <b>2011</b> , 43, 761-7	36.3	646
183	Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?. <i>Current Rheumatology Reports</i> , <b>2011</b> , 13, 346-52	4.9	15
182	Incidence of arthritis in a prospective cohort of psoriasis patients. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 619-22	4.7	56
181	Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1091-7	4.7	81
180	Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1440-7	4.7	23
179	Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1517-20	4.7	20
178	Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. <i>Arthritis Care and Research</i> , <b>2011</b> , 63, 1729-35	4.7	169
177	Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 939-48		218
176	Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 69-78	4.1	84
175	Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 305-8	2.4	34
174	Cardiovascular comorbidities in psoriasis and psoriatic arthritis: pathogenesis, consequences for patient management, and future research agenda: a report from the GRAPPA 2009 annual meeting. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 567-71	4.1	22
173	Effectiveness and safety of etanercept in patients with psoriatic arthritis in a Canadian clinical practice setting: the REPARÉ trial. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1355-62	4.1	24
172	SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. <i>Lupus</i> , <b>2011</b> , 20, 67-70	2.6	65
171	Patient-reported outcome in psoriatic arthritis: a comparison of Web-based versus paper-completed questionnaires. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 2619-24	4.1	25

170	Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 2152-4	2.4	145
169	Measuring participation in people with spondyloarthritis using the social role participation questionnaire. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1765-9	2.4	16
168	Thrombovascular events affect quality of life in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1017-9	4.1	12
167	Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 522-5	4.1	4
166	Development of a disease severity and responder index for psoriatic arthritis (PsA)--report of the OMERACT 10 PsA special interest group. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1496-501	4.1	30
165	Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1898-905	4.1	56
164	Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 898-903	4.1	82
163	Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus. <i>Lupus</i> , <b>2011</b> , 20, 299-304	2.6	9
162	Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 275-84	4.1	54
161	The Spondyloarthritis Research Consortium of Canada registry for spondyloarthritis. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1343-8	4.1	15
160	Repair of radiographic joint damage following treatment with etanercept in psoriatic arthritis is demonstrable by 3 radiographic methods. <i>Journal of Rheumatology</i> , <b>2011</b> , 38, 1066-70	4.1	18
159	Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. <i>Nature Genetics</i> , <b>2010</b> , 42, 991-5	36.3	283
158	Genome-wide association analysis identifies three psoriasis susceptibility loci. <i>Nature Genetics</i> , <b>2010</b> , 42, 1000-4	36.3	251
157	Informing response criteria for psoriatic arthritis. I: discrimination models based on data from 3 anti-tumor necrosis factor randomized studies. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1892-7	4.1	24
156	Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. <i>Rheumatology</i> , <b>2010</b> , 49, 1361-6	3.9	23
155	Early-onset obesity and risk for psoriatic arthritis. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 787-8	27.4	6
154	Responses to adalimumab in patients with active psoriatic arthritis who have not adequately responded to prior therapy: effectiveness and safety results from an open-label study. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1898-906	4.1	50
153	Composite measures in psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 453-61	4.1	21

152	The effect of lupus nephritis on pregnancy outcome and fetal and maternal complications. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 754-8	4.1	91
151	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 446-7	4.1	2
150	Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1885-91	4.1	31
149	Vitamin D insufficiency in a large female SLE cohort. <i>Lupus</i> , <b>2010</b> , 19, 13-9	2.6	131
148	SLEDAI-2K for a 30-day window. <i>Lupus</i> , <b>2010</b> , 19, 49-51	2.6	55
147	Predictors of response to intra-articular steroid injection in psoriatic arthritis. <i>Rheumatology</i> , <b>2010</b> , 49, 1367-73	3.9	51
146	Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 2160-4	2.4	57
145	Imaging in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 448-52	4.1	14
144	Informing response criteria for psoriatic arthritis (PsA). II: Further considerations and a proposal—the PsA joint activity index. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 2559-65	4.1	25
143	Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. <i>Rheumatology</i> , <b>2010</b> , 49, 1399-405	3.9	118
142	Biomarkers in psoriasis and psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 462-7	4.1	10
141	Longitudinal analysis of fatigue in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1878-84	4.1	28
140	Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1508-12	4.1	38
139	Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 1822-7	4.1	90
138	Risk factors for axial inflammatory arthritis in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 809-15	4.1	61
137	Psoriasis in patients with HIV infection: from the medical board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 62, 291-9	4.5	98
136	Recognizing psoriatic arthritis in the dermatology clinic. <i>Journal of the American Academy of Dermatology</i> , <b>2010</b> , 63, 733-48; quiz 749-50	4.5	21
135	Management of Psoriatic Arthritis <b>2010</b> , 55-69		1

134	Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R113	5.7	59
133	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R125	5.7	20
132	Update on biomarkers in psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 288-94	4.9	29
131	Development of screening tools to identify psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2010</b> , 12, 295-9	4.9	23
130	Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. <i>Arthritis Care and Research</i> , <b>2010</b> , 62, 970-6	4.7	94
129	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 863-8		203
128	Association of interleukin 23 receptor variants with psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 137-40	4.1	56
127	Axial psoriatic arthritis: update on a longterm prospective study. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2744-50	4.1	69
126	Significance of clinical evaluation of the metacarpophalangeal joint in relation to synovial/bone pathology in rheumatoid and psoriatic arthritis detected by magnetic resonance imaging. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2751-7	4.1	17
125	Spondyloarthropathies: Targeted therapy for psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , <b>2009</b> , 5, 241-2	8.1	4
124	Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1785-91	4.1	35
123	Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. <i>Lupus</i> , <b>2009</b> , 18, 966-73	2.6	18
122	Myocardial perfusion imaging in assessing risk of coronary events in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 288-94	4.1	26
121	Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 976-86		467
120	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1235-42		83
119	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 61, 1152-8		90
118	Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. <i>Nature Genetics</i> , <b>2009</b> , 41, 199-204	36.3	1038
117	Psoriatic arthritis. <i>Dermatologic Therapy</i> , <b>2009</b> , 22, 40-55	2.2	101

116	Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 2454-61	4.1	57
115	Psoriatic arthritis from Wright® era until today. <i>Journal of rheumatology Supplement, The</i> , <b>2009</b> , 83, 4-8		22
114	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , <b>2008</b> , 58, 1031-42	4.5	329
113	Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn® disease. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , <b>2008</b> , 8, 111-25	2.2	
112	Changing patterns in mortality and disease outcomes for patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2152-8	4.1	229
111	Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , <b>2008</b> , 4, 510-1		22
110	Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus. <i>Lupus</i> , <b>2008</b> , 17, 793-8	2.6	11
109	The SLICC inception cohort for atherosclerosis. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 281-5	4.9	9
108	Can we identify psoriatic arthritis early?. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 419-21	4.9	5
107	Prevalence of malignancy in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 82-7		64
106	Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 556-62		354
105	Quality of life over time in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 59, 181-5		104
104	Association of interleukin-23 receptor variants with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1020-5		134
103	A variant of the IL4 I50V single-nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 2207-8		16
102	Genetics of psoriasis and psoriatic arthritis: update and future direction. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1449-53	4.1	70
101	Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 469-71	4.1	56
100	GRAPPA 2007: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1420-2	4.1	1
99	Clinical and genetic registries in psoriatic disease. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 1458-63	4.1	8



98	Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. <i>Journal of Rheumatology</i> , <b>2008</b> , 35, 2069-70; author reply 2070	4.1	42
97	Clinical Features of Psoriatic Arthritis <b>2007</b> , 11-18		
96	Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 476-88		231
95	A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 840-9		76
94	Improved survival in psoriatic arthritis with calendar time. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 56, 2708-14		85
93	Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 1560-3		98
92	Axial disease in psoriatic arthritis. <i>Current Rheumatology Reports</i> , <b>2007</b> , 9, 455-60	4.9	78
91	Predictors for radiological damage in psoriatic arthritis: results from a single centre. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 370-6	2.4	104
90	Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 936-9	2.4	112
89	Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 70-5	4.1	83
88	Summarizing disease features over time: II. Variability measures of SLEDAI-2K. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 336-40	4.1	23
87	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1167-70	4.1	144
86	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1733-9	4.1	48
85	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 1740-5	4.1	67
84	Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 2463-5	4.1	17
83	Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 974-85		64
82	Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 1638-45		122
81	Association between the interleukin-1 family gene cluster and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2321-5		104

80	Classification criteria for psoriatic arthritis: development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , <b>2006</b> , 54, 2665-73		2136
79	A novel, disease-specific quality-of-life instrument for patients with SLE. <i>Nature Clinical Practice Rheumatology</i> , <b>2006</b> , 2, 132-3		2
78	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1990-5	4.1	41
77	Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1785-8	4.1	35
76	Contributions of observational cohort studies in systemic lupus erythematosus: the university of toronto lupus clinic experience. <i>Rheumatic Disease Clinics of North America</i> , <b>2005</b> , 31, 211-21, v	2.4	48
75	Epidemiology of psoriatic arthritis in the population of the United States. <i>Journal of the American Academy of Dermatology</i> , <b>2005</b> , 53, 573	4.5	414
74	Traditional and newer therapeutic options for psoriatic arthritis: an evidence-based review. <i>Drugs</i> , <b>2005</b> , 65, 1223-38	12.1	13
73	Spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , <b>2005</b> , 17, 393-394	5.3	
72	Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 1227-36		517
71	Description and prediction of physical functional disability in psoriatic arthritis: a longitudinal analysis using a Markov model approach. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 53, 404-9		49
70	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , <b>2005</b> , 52, 3279-89		712
69	Longitudinal cohort studies. <i>Journal of rheumatology Supplement, The</i> , <b>2005</b> , 72, 30-2		3
68	Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 824-7	4.1	97
67	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1467-72	4.1	76
66	HLA markers for susceptibility and expression in scleroderma. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1481-74.1		43
65	Outcome measures in psoriatic arthritis. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2262-9	4.1	33
64	Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 2364-7	4.1	3
63	Cutting edge: heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. <i>Journal of Immunology</i> , <b>2004</b> , 173, 4273-6	5.3	224

62	Psoriatic arthritis. <i>Dermatologic Therapy</i> , <b>2004</b> , 17, 350-63	2.2	57
61	Assessment of patients with psoriatic arthritis: a review of currently available measures. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 24-35		151
60	Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 1939-50		298
59	The effect of pregnancy on lupus nephritis. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 3941-6		92
58	Current and investigational treatment of psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , <b>2004</b> , 13, 139-50	5.9	7
57	The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. <i>Journal of Rheumatology</i> , <b>2004</b> , 31, 1126-31	4.1	57
56	Effectiveness of psoriatic arthritis therapies. <i>Seminars in Arthritis and Rheumatism</i> , <b>2003</b> , 33, 29-37	5.3	24
55	HLA is a candidate region for psoriatic arthritis. evidence for excessive HLA sharing in sibling pairs. <i>Human Immunology</i> , <b>2003</b> , 64, 887-9	2.3	45
54	CARD15: a pleiotropic autoimmune gene that confers susceptibility to psoriatic arthritis. <i>American Journal of Human Genetics</i> , <b>2003</b> , 73, 677-81	11	136
53	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 288-91	4.1	25
52	Clinical and radiological changes during psoriatic arthritis disease progression. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1022-6	4.1	35
51	Accrual of organ damage over time in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1955-9	4.1	185
50	Clinically active serologically quiescent systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1960-2	4.1	35
49	Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. <i>Journal of Rheumatology</i> , <b>2003</b> , 30, 1977-82	4.1	108
48	Cutting edge: susceptibility to psoriatic arthritis: influence of activating killer Ig-like receptor genes in the absence of specific HLA-C alleles. <i>Journal of Immunology</i> , <b>2002</b> , 169, 2818-22	5.3	287
47	Current concepts in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , <b>2002</b> , 14, 361-6	5.3	34
46	Diagnosis and management of psoriatic arthritis. <i>Drugs</i> , <b>2002</b> , 62, 2447-57	12.1	56
45	Systemic lupus erythematosus disease activity index 2000. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 288-91	4.1	1602

44	The rate and pattern of organ damage in late onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , <b>2002</b> , 29, 913-7	4.1	71
43	Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2001</b> , 45, 151-8		257
42	HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. <i>Human Immunology</i> , <b>2001</b> , 62, 1239-44	2.3	19
41	The long-term use of azathioprine in patients with psoriatic arthritis. <i>Journal of Clinical Rheumatology</i> , <b>2001</b> , 7, 160-5	1.1	26
40	Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis <b>2001</b> , 45, 151		2
39	Hyperuricemia in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , <b>2000</b> , 6, 6-9	1.1	35
38	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 13, 406-408		44
37	Psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , <b>2000</b> , 9, 1511-22	5.9	61
36	Premature atherosclerosis in systemic lupus erythematosus. <i>Rheumatic Disease Clinics of North America</i> , <b>2000</b> , 26, 257-78	2.4	101
35	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence <b>2000</b> , 13, 406		3
34	Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 822-3		79
33	Excessive paternal transmission in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>1999</b> , 42, 1228-31		66
32	HLA-C locus alleles in patients with psoriatic arthritis (PsA). <i>Human Immunology</i> , <b>1999</b> , 60, 259-61	2.3	73
31	Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 1103-10		246
30	Assessing lupus. <i>Arthritis and Rheumatism</i> , <b>1998</b> , 41, 2276-2276		1
29	Psoriatic arthritis. <i>Rheumatic Disease Clinics of North America</i> , <b>1998</b> , 24, 829-44, x	2.4	90
28	Psoriatic arthritis: recognition and management. <i>BioDrugs</i> , <b>1998</b> , 9, 271-8	7.9	10
27	Clinical Aspects of the Spondyloarthropathies. <i>American Journal of the Medical Sciences</i> , <b>1998</b> , 316, 234-238		20

26	Clinical aspects of the spondyloarthropathies. <i>American Journal of the Medical Sciences</i> , <b>1998</b> , 316, 234-82.2		53
25	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 809-13		505
24	Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. <i>Arthritis and Rheumatism</i> , <b>1997</b> , 40, 1868-72		269
23	A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). <i>Lupus</i> , <b>1996</b> , 5, 190-5	2.6	70
22	The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 363-9		1688
21	Malignancy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1996</b> , 39, 1050-4		179
20	Psoriatic arthritis. <i>Bailliere's Clinical Rheumatology</i> , <b>1995</b> , 9, 319-29		46
19	The role of HLA antigens as indicators of disease progression in psoriatic arthritis. Multivariate relative risk model. <i>Arthritis and Rheumatism</i> , <b>1995</b> , 38, 845-50		88
18	Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. <i>Arthritis and Rheumatism</i> , <b>1994</b> , 37, 1212-20		89
17	Natural history of psoriatic arthritis. <i>Bailliere's Clinical Rheumatology</i> , <b>1994</b> , 8, 379-94		87
16	Lupus and pregnancy studies. <i>Arthritis and Rheumatism</i> , <b>1993</b> , 36, 1392-7		183
15	Assessment of disease activity in lupus. <i>Transfusion Science</i> , <b>1992</b> , 13, 129-134		1
14	HLA antigens in North American patients with Takayasu arteritis. <i>Arthritis and Rheumatism</i> , <b>1992</b> , 35, 573-5		30
13	Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. <i>Arthritis and Rheumatism</i> , <b>1992</b> , 35, 630-40		3596
12	PSORIATIC ARTHRITIS: RECENT ADVANCES IN PATHOGENESIS AND TREATMENT. <i>Rheumatic Disease Clinics of North America</i> , <b>1992</b> , 18, 247-256	2.4	21
11	Psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , <b>1990</b> , 2, 577-81	5.3	6
10	Atlantoaxial subluxation in a patient with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , <b>1989</b> , 32, 1338-9		7
9	Lupus retinopathy. Patterns, associations, and prognosis. <i>Arthritis and Rheumatism</i> , <b>1988</b> , 31, 1105-10		161

8	HLA-DR4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. <i>Arthritis and Rheumatism</i> , <b>1987</b> , 30, 1293-7		56
7	Bowel involvement in systemic lupus erythematosus: Crohn's disease or lupus vasculitis?. <i>Arthritis and Rheumatism</i> , <b>1985</b> , 28, 466-70		23
6	The significance of thrombocytopenia in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , <b>1983</b> , 26, 1181-6		51
5	Impaired antigen-specific suppressor cell activity in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>1980</b> , 23, 1246-50		45
4	Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. <i>American Journal of Medicine</i> , <b>1979</b> , 66, 210-5	2.4	117
3	Mixed leukocyte reaction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>1976</b> , 19, 532-8		10
2	Inhibition of mitogen mediated lymphocyte blastogenesis by adenosine. <i>Immunological Investigations</i> , <b>1975</b> , 4, 419-27		31
1	Current and investigational treatment of psoriatic arthritis		1